IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal.
Hypoglycemia is a rare paraneoplastic manifestation of patients with neoplasms. Hypoglycemia can be induced by several causes, including an aberrant increase of hypoglycemic agents and adrenal insufficiency. Sorafenib is the first agent to demonstrate a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC). This small molecule inhibits serine/threonine kinase RAF in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature and decreases tumor growth and angiogenesis. In this paper, we report a case of HCC who was treated with sorafenib and showed severe hypoglycemia. This hypoglycemia might be induced by two causes, both adrenal insufficiency as an adverse effect of sorafenib and activation of the insulin-like growth factor (IGF) signal by excessive secretion of incompletely processed precursors of IGF-II. Although the IGF signal is suggested to be involved in aberrant growth of HCC in some cases, there is no other report showing the influence of sorafenib on HCC with active IGF signal. Unfortunately, the effect of sorafenib was limited in the present case. However, emerging drugs that directly inhibit the IGF signal can be expected to be highly effective in the treatment of HCC with hypoglycemia.
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Kazuya
K
Okushin
Yoshinari
Y
Asaoka
Izumi
I
Fukuda
Naoto
N
Fujiwara
Tatsuya
T
Minami
Masaya
M
Sato
Shintaro
S
Mikami
Koji
K
Uchino
Kenichiro
K
Enooku
Yuji
Y
Kondo
Ryosuke
R
Tateishi
Tadashi
T
Goto
Shuichiro
S
Shiina
Haruhiko
H
Yoshida
Kazuhiko
K
Koike
Hepatocellular carcinoma; Hypoglycemia; IGF signal; IGF-II; Metabolic complications; Molecular targeting therapy; Sorafenib